Submit an Investigational New Drug application for a Phase 2 achondroplasia study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Aug 2024
- Due
- 31 Dec 2024
- Delivered
- October 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“TYRA remains on track to submit an Investigational New Drug application (IND) to the FDA in the second half of 2024 for the initiation of a Phase 2 clinical trial”
What we found
Evidence strength A What the grades mean
The company announced in October 2024 that the FDA cleared its IND for a Phase 2 clinical trial of TYRA-300 for children with achondroplasia, meeting the second-half 2024 deadline.
-
A Tyra Biosciences, Inc. 10-K filed 2025-03-27
“In October 2024, we announced that the FDA cleared the Company’s IND for TYRA-300 to proceed with a Phase 2 clinical trial of TYRA-300 for children with ACH (BEACH301).” ✓ confirmed on the page
Market reaction: the shares moved -7.6% against the S&P 500 over the three sessions around the disclosure (26 Mar 2025 to 31 Mar 2025). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- IND application for Phase 2 achondroplasia study
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Tyra Biosciences, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-TYRA-002078 · Corrections policy